Laurie H. Sehn, MD, Discusses Preliminary Findings From the GO29365 Study in DLBCL

The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.

In an interview with CancerNetwork®, Laurie H. Sehn, MD, of the BC Cancer Centre for Lymphoid Cancer, discussed preliminary results from the extension arm of the phase 2 GO29365 study evaluating the safety and efficacy of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) versus bendamustine plus rituximab alone for patients with diffuse large B-cell lymphoma (DLBCL).


It was preliminary results from the extended arm that was presented. So, median follow up time was 15 months at the time of analysis, as compared to 49 months that we have on the original cohort. But what was highly encouraging is that the results are quite comparable. Importantly, the eligibility criteria were the same. So, it was designed to enroll patients with transplant ineligible diffuse large B-cell lymphoma. And quite generally, I'd say that the characteristics between the original randomized polatuzumab-BR arm and the extension cohort were quite similar. Although, the patients in the extension cohort were a little bit older, and there was a higher percentage of patients that had primary refractory disease. So perhaps a little bit higher risk than the polatuzumab-BR randomized arm. But despite that, in the short follow up, what we saw was that the complete response rate, which was 39%, was very much in keeping with what was recorded in the initial randomized phase 2 arm. And similarly, the median overall survival, which was in the range of 12 months was also very comparable. So, it really serves to further affirm the benefit of this combination, and very much demonstrates similar findings.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Related Content